Liraglutide Use in Prader-Willi Syndrome

NCT01542242 · Terminated

Last updated 2026-05-28

This clinical trial is testing the effects of the medication liraglutide in people with Prader-Willi syndrome who also have type 2 diabetes.

Status Terminated Stopped early and will not restart.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 1 person

Who can join Ages 19+ · male only Healthy volunteers accepted.

Timeline Started 2012-02 · est. completion 2013-03

Where 1 site · Canada

What this study is testing ClinicalTrials.gov NCT01542242 ↗

Description as written by the study sponsor.

Liraglutide is a glucagon like peptide -1 (GLP-1) agonist, which is approved for use in patients with type 2 diabetes. Studies of liraglutide have shown an appetite suppressive effect and has been associated with weight loss in patients with type 2 diabetes. Liraglutide use in the treatment of PWS is limited to one case report by Cyganek et el (See attached Citation). In this case report, the subject showed improvements in hemoglobin A1c and body weight over 14 weeks. The investigators plan to examine the use of liraglutide in a single subject with Prader Willi Syndrome and type 2 diabetes for one year. The investigators will examine clinical parameters, clinical assessment of hunger, and biochemical markers of diabetes and lipid control.

Treatments tested

Liraglutide also known as Victoza Drug

Liraglutide 0.6 mg SQ daily for one week, increase to a maximum dose of 1.8 mg SQ daily by 6 weeks, and subsequent continuation for the remainder of a year.

Main thing measured	Hemoglobin A1C
Sponsor	Vancouver General Hospital
Conditions studied	Diabetes Mellitus Type 2, Prader Willi Syndrome
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01542242 ↗